Detailed Information on Publication Record
2019
Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia
KRÁL, Zdeněk, Jozef MICHALKA, Heidi MOCIKOVA, Jana MARKOVA, Alice SYKOROVA et. al.Basic information
Original name
Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia
Authors
KRÁL, Zdeněk (203 Czech Republic, guarantor, belonging to the institution), Jozef MICHALKA (703 Slovakia, belonging to the institution), Heidi MOCIKOVA (203 Czech Republic), Jana MARKOVA (203 Czech Republic), Alice SYKOROVA (203 Czech Republic), David BELADA (203 Czech Republic), Alexandra JUNGOVA (203 Czech Republic), Samuel VOKURKA (203 Czech Republic), Marie LUKASOVA (203 Czech Republic), Vit PROCHAZKA (203 Czech Republic), Juraj DURAS (203 Czech Republic), Roman HAJEK (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), L'ubos DRGONA (703 Slovakia), Miriam LADICKA (703 Slovakia), Veronika BALLOVA (756 Switzerland) and Andrei VRANOVSKY (703 Slovakia)
Edition
Journal of Cancer, Australia, IVYSPRING INT PUBL, 2019, 1837-9664
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Australia
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.565
RIV identification code
RIV/00216224:14110/19:00111949
Organization unit
Faculty of Medicine
UT WoS
000484111400004
Keywords in English
antibody-drug conjugate; CD30; brentuximab vedotin; Hodgkin lymphoma; registries; stem cell transplantation
Tags
International impact, Reviewed
Změněno: 11/5/2020 10:38, Mgr. Tereza Miškechová
Abstract
V originále
Introduction: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody- drug conjugate brentuximab vedotin (BV) for the treatment of relapsed/refractory Hodgkin lymphoma (R/R HL). In this study, we report on outcomes with BV in a real-world setting using data collected in clinics in the Czech Republic and Slovakia. Patients and Methods: Clinical and epidemiological data for patients with R/R HL who received treatment with BV at eight centers across the Czech Republic and Slovakia were examined. Data were amalgamated and analyzed retrospectively. Results: Clinical data for 58 patients (median age: 30.5 years) with R/R HL who received BV during the course of their treatment were collected and analyzed. Patients had received a median of 3 prior treatment regimens and most (91%) were treated with BV after relapse following autologous stem cell transplantation. Therapeutic responses after BV included 19 (33%) complete responses (CRs) and 8 (14%) partial responses. CRs occurred more frequently in patients who had received fewer prior treatment regimens. The 1-, 2-, and 3-year overall survival (OS) rates from initiation of BV were 78%, 62%, and 41%, respectively. Conclusion: Response rates and OS in this analysis of BV in real-world settings in the Czech Republic and Slovakia were consistent with those reported for pivotal clinical trials and from previous studies outside the clinical trial setting. The results support the efficacy of BV for treatment of R/R HL in real-life clinical practice.